Bristol Questran OTC switch for cholesterol lowering set for advisory committee review.
BRISTOL QUESTRAN OTC SWITCH APPLICATION ADVISORY COMMITTEE REVIEW by FDA's Nonprescription Drugs and Endocrinologic & Metabolic Drugs Advisory Committees is set for Sept. 27. The committees will review data from Bristol-Myers Squibb's Rx-to-OTC switch NDAs for the cholestyramine products Questran and Questran Light (NDAs 16-640 and 19-669). Both Questran and Questran Light are intended as adjunctive therapies for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low-density lipoprotein) who do not respond adequately to diet alone. Bristol's Questran NDAs are the first switch applications for cholesterol-lowering drugs to reach FDA advisory committee review.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth